Genmab

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from growing back in people whose cancer had previously responded to platinum chemotherapy. About 528 adults with recurrent platinum-sensitive ovarian cancer will receive ei…

This study tests a new drug called rinatabart sesutecan (Rina-S) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the activ…

This study tests a drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to check safety and see if the drug shrinks tumors. About 764 participants with cancers like ovarian, lung, breast, or endometrial cancer will t…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. All participants receive the active drug, and treatment may continue as long as it helps and side …

This study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has come back or worsened after prior treatment. About 660 participants will be randomly assigned to receive either Rina-S or a standard chemo …

This study tests whether adding the experimental drug epcoritamab to standard treatments (rituximab and lenalidomide) works better than usual chemo for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assigned to differen…

This early-stage trial tests a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then, refining the dose; and finally, checking how well it works in more patients. About 121 participants will receive t…

This study is for adults with Non-Hodgkin lymphoma, a type of blood cancer. It tests a new drug called epcoritamab combined with other cancer medicines to see if it is safe and helps shrink tumors. About 496 people will take part at hospitals around the world. The goal is to find…

This early-stage trial tests a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the right dose for future studies.…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; then refining that dose; and finally, checking how well the drug works in a specific canc…